View ValuationRobertet 将来の成長Future 基準チェック /26Robertet利益と収益がそれぞれ年間7.2%と5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に15.6% 7.5%なると予測されています。主要情報7.2%収益成長率7.49%EPS成長率Chemicals 収益成長39.3%収益成長率5.0%将来の株主資本利益率15.63%アナリストカバレッジGood最終更新日19 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesDeclared Dividend • May 04Dividend increased to €12.00Dividend of €12.00 is 20% higher than last year. Ex-date: 29th June 2026 Payment date: 1st July 2026 Dividend yield will be 1.5%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (25% earnings payout ratio) and cash flows (38% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 25% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Apr 28Robertet SA, Annual General Meeting, Jun 03, 2026Robertet SA, Annual General Meeting, Jun 03, 2026. Location: 48 avenue jean maubert, grasse FranceReported Earnings • Apr 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €849.8m (up 5.2% from FY 2024). Net income: €103.4m (up 15% from FY 2024). Profit margin: 12% (up from 11% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom.お知らせ • Apr 11Robertet SA Proposes Dividend for the Year 2025Robertet SA announced the Annual General Meeting will be held on June 3, 2026 and the shareholders will be invited to approve a dividend payment of €12 per share, up 20% on the previous year owing to Robertet's strong results in 2025.お知らせ • Feb 12Robertet SA to Report First Half, 2026 Final Results on Sep 21, 2026Robertet SA announced that they will report first half, 2026 final results on Sep 21, 2026Board Change • Jan 16Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Lucie Maurel-Aubert was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 02+ 2 more updatesRobertet SA to Report Fiscal Year 2025 Results on Apr 09, 2026Robertet SA announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 09, 2026お知らせ • Sep 12Robertet SA to Report First Half, 2025 Final Results on Sep 18, 2025Robertet SA announced that they will report first half, 2025 final results on Sep 18, 2025お知らせ • Jul 25Robertet SA to Report First Half, 2025 Results on Sep 11, 2025Robertet SA announced that they will report first half, 2025 results on Sep 11, 2025Upcoming Dividend • Jun 20Upcoming dividend of €10.00 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 01 July 2025. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (4.1%).お知らせ • Apr 29Robertet SA, Annual General Meeting, Jun 04, 2025Robertet SA, Annual General Meeting, Jun 04, 2025. Location: 48 avenue jean maubert, grasse FranceDeclared Dividend • Apr 28Dividend increased to €10.00Dividend of €10.00 is 18% higher than last year. Ex-date: 27th June 2025 Payment date: 1st July 2025 Dividend yield will be 1.2%, which is lower than the industry average of 3.0%.お知らせ • Nov 06Robertet SA (ENXTPA:RBT) agreed to acquire Phasex Corporation.Robertet SA (ENXTPA:RBT) agreed to acquire Phasex Corporation on November 4, 2024.Reported Earnings • Sep 27First half 2024 earnings released: EPS: €24.71 (vs €19.14 in 1H 2023)First half 2024 results: EPS: €24.71 (up from €19.14 in 1H 2023). Revenue: €414.6m (up 10% from 1H 2023). Net income: €51.7m (up 29% from 1H 2023). Profit margin: 13% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 5.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Board Change • Jun 06High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Lucie Maurel-Aubert was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 22Full year 2023 earnings released: EPS: €35.71 (vs €32.85 in FY 2022)Full year 2023 results: EPS: €35.71. Revenue: €735.6m (up 4.6% from FY 2022). Net income: €74.6m (down 1.9% from FY 2022). Profit margin: 10% (in line with FY 2022). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 2.4% decline forecast for the Chemicals industry in the United Kingdom.New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.お知らせ • Apr 12+ 2 more updatesRobertet SA to Report First Half, 2024 Results on Sep 23, 2024Robertet SA announced that they will report first half, 2024 results on Sep 23, 2024Buy Or Sell Opportunity • Apr 09Now 20% undervaluedOver the last 90 days, the stock has risen 1.8% to €807. The fair value is estimated to be €1,011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.Buy Or Sell Opportunity • Feb 21Now 22% undervaluedOver the last 90 days, the stock has risen 4.5% to €794. The fair value is estimated to be €1,024, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.Buy Or Sell Opportunity • Feb 21Now 22% undervaluedOver the last 90 days, the stock has risen 4.8% to €794. The fair value is estimated to be €1,022, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.Reported Earnings • Oct 05First half 2023 earnings released: EPS: €19.13 (vs €19.49 in 1H 2022)First half 2023 results: EPS: €19.13 (down from €19.49 in 1H 2022). Revenue: €376.4m (up 4.9% from 1H 2022). Net income: €39.9m (down 11% from 1H 2022). Profit margin: 11% (down from 13% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 5.1% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Upcoming Dividend • Jun 22Upcoming dividend of €8.50 per share at 1.0% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 26% and the cash payout ratio is 77%. Trailing yield: 1.0%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (2.8%).Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Director Elie Vannier was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • May 01Full year 2021 earnings releasedFull year 2021 results: Revenue: €608.8m (up 13% from FY 2020). Net income: €71.7m (up 42% from FY 2020). Profit margin: 12% (up from 9.4% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 11% compared to a 16% decline forecast for the industry in the United Kingdom.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 01First half 2021 earnings released: EPS €16.47 (vs €13.03 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €297.6m (up 6.2% from 1H 2020). Net income: €38.1m (up 27% from 1H 2020). Profit margin: 13% (up from 11% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 05Full year 2020 earnings released: EPS €21.88 (vs €22.96 in FY 2019)The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €538.3m (down 2.9% from FY 2019). Net income: €50.6m (down 4.7% from FY 2019). Profit margin: 9.4% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Jan 29New 90-day high: €955The company is up 3.0% from its price of €923 on 30 October 2020. The British market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 20% over the same period.Is New 90 Day High Low • Dec 11New 90-day low: €546The company is down 45% from its price of €996 on 11 September 2020. The British market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period.Valuation Update With 7 Day Price Move • Dec 11Investor sentiment deteriorated over the past weekAfter last week's 38% share price decline to €546, the stock is trading at a trailing P/E ratio of 36.9x, down from the previous P/E ratio of 59.8x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 40%.Valuation Update With 7 Day Price Move • Dec 10Market pulls back on stock over the past weekAfter last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 36.9x, down from the previous P/E ratio of 60.7x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Valuation Update With 7 Day Price Move • Dec 07Market pulls back on stock over the past weekAfter last week's 40% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.3x, down from the previous P/E ratio of 63.4x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Valuation Update With 7 Day Price Move • Dec 03Market pulls back on stock over the past weekAfter last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 63.2x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Valuation Update With 7 Day Price Move • Nov 30Market pulls back on stock over the past weekAfter last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 63.8x. This compares to an average P/E of 38x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Valuation Update With 7 Day Price Move • Nov 27Market pulls back on stock over the past weekAfter last week's 40% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 64.1x. This compares to an average P/E of 37x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Valuation Update With 7 Day Price Move • Nov 24Market pulls back on stock over the past weekAfter last week's 42% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 66.8x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Is New 90 Day High Low • Nov 20New 90-day low: €546The company is down 39% from its price of €897 on 21 August 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period.Valuation Update With 7 Day Price Move • Nov 20Market pulls back on stock over the past weekAfter last week's 42% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 66.8x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Is New 90 Day High Low • Oct 12New 90-day high: €1,036The company is up 8.0% from its price of €958 on 13 July 2020. The British market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 10.0% over the same period.Reported Earnings • Oct 02First half earnings releasedOver the last 12 months the company has reported total profits of €53.7m, largely unchanged from the prior year. Total revenue was €547.4m over the last 12 months, up 1.0% from the prior year.業績と収益の成長予測LSE:0NZN - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202897712192148512/31/202791811086142812/31/202687110065134712/31/202584410367111N/A9/30/202584210063105N/A6/30/2025839975999N/A3/31/20258249367106N/A12/31/20248089074112N/A9/30/20247838883114N/A6/30/20247598691115N/A3/31/20247408088108N/A12/31/20237217584102N/A9/30/2023721737795N/A6/30/2023721717088N/A3/31/2023712734768N/A12/31/2022703762447N/A9/30/2022685772751N/A6/30/2022667793155N/A3/31/2022637754770N/A12/31/2021606726485N/A9/30/2021581656281N/A6/30/2021556596077N/A3/31/2021547557389N/A12/31/20205385186101N/A9/30/2020543528098N/A6/30/2020547547496N/A3/31/2020551536184N/A12/31/2019554534772N/A9/30/201954853N/A67N/A6/30/201954254N/A61N/A3/31/201953353N/A56N/A12/31/201852552N/A51N/A9/30/201852051N/A46N/A6/30/201851651N/A41N/A3/31/201851050N/A40N/A12/31/201750449N/A39N/A9/30/201749647N/A39N/A6/30/201748845N/A39N/A3/31/201747843N/A35N/A12/31/201646842N/A32N/A9/30/201646340N/A26N/A6/30/201645739N/A20N/A3/31/201644637N/A20N/A12/31/201543536N/A21N/A9/30/201542334N/A23N/A6/30/201541033N/A24N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 0NZNの予測収益成長率 (年間7.2% ) は 貯蓄率 ( 3.4% ) を上回っています。収益対市場: 0NZNの収益 ( 7.2% ) UK市場 ( 11.5% ) よりも低い成長が予測されています。高成長収益: 0NZNの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 0NZNの収益 ( 5% ) UK市場 ( 4.5% ) よりも速いペースで成長すると予測されています。高い収益成長: 0NZNの収益 ( 5% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 0NZNの 自己資本利益率 は、3年後には低くなると予測されています ( 15.6 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 16:14終値2026/05/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Robertet SA 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15 アナリスト機関Fraser DonlonBerenbergMarie-Line FortBernsteinNicola TangBNP Paribas12 その他のアナリストを表示
Declared Dividend • May 04Dividend increased to €12.00Dividend of €12.00 is 20% higher than last year. Ex-date: 29th June 2026 Payment date: 1st July 2026 Dividend yield will be 1.5%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (25% earnings payout ratio) and cash flows (38% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 25% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Apr 28Robertet SA, Annual General Meeting, Jun 03, 2026Robertet SA, Annual General Meeting, Jun 03, 2026. Location: 48 avenue jean maubert, grasse France
Reported Earnings • Apr 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €849.8m (up 5.2% from FY 2024). Net income: €103.4m (up 15% from FY 2024). Profit margin: 12% (up from 11% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom.
お知らせ • Apr 11Robertet SA Proposes Dividend for the Year 2025Robertet SA announced the Annual General Meeting will be held on June 3, 2026 and the shareholders will be invited to approve a dividend payment of €12 per share, up 20% on the previous year owing to Robertet's strong results in 2025.
お知らせ • Feb 12Robertet SA to Report First Half, 2026 Final Results on Sep 21, 2026Robertet SA announced that they will report first half, 2026 final results on Sep 21, 2026
Board Change • Jan 16Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Lucie Maurel-Aubert was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 02+ 2 more updatesRobertet SA to Report Fiscal Year 2025 Results on Apr 09, 2026Robertet SA announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 09, 2026
お知らせ • Sep 12Robertet SA to Report First Half, 2025 Final Results on Sep 18, 2025Robertet SA announced that they will report first half, 2025 final results on Sep 18, 2025
お知らせ • Jul 25Robertet SA to Report First Half, 2025 Results on Sep 11, 2025Robertet SA announced that they will report first half, 2025 results on Sep 11, 2025
Upcoming Dividend • Jun 20Upcoming dividend of €10.00 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 01 July 2025. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (4.1%).
お知らせ • Apr 29Robertet SA, Annual General Meeting, Jun 04, 2025Robertet SA, Annual General Meeting, Jun 04, 2025. Location: 48 avenue jean maubert, grasse France
Declared Dividend • Apr 28Dividend increased to €10.00Dividend of €10.00 is 18% higher than last year. Ex-date: 27th June 2025 Payment date: 1st July 2025 Dividend yield will be 1.2%, which is lower than the industry average of 3.0%.
お知らせ • Nov 06Robertet SA (ENXTPA:RBT) agreed to acquire Phasex Corporation.Robertet SA (ENXTPA:RBT) agreed to acquire Phasex Corporation on November 4, 2024.
Reported Earnings • Sep 27First half 2024 earnings released: EPS: €24.71 (vs €19.14 in 1H 2023)First half 2024 results: EPS: €24.71 (up from €19.14 in 1H 2023). Revenue: €414.6m (up 10% from 1H 2023). Net income: €51.7m (up 29% from 1H 2023). Profit margin: 13% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 5.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Board Change • Jun 06High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Lucie Maurel-Aubert was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 22Full year 2023 earnings released: EPS: €35.71 (vs €32.85 in FY 2022)Full year 2023 results: EPS: €35.71. Revenue: €735.6m (up 4.6% from FY 2022). Net income: €74.6m (down 1.9% from FY 2022). Profit margin: 10% (in line with FY 2022). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 2.4% decline forecast for the Chemicals industry in the United Kingdom.
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.
お知らせ • Apr 12+ 2 more updatesRobertet SA to Report First Half, 2024 Results on Sep 23, 2024Robertet SA announced that they will report first half, 2024 results on Sep 23, 2024
Buy Or Sell Opportunity • Apr 09Now 20% undervaluedOver the last 90 days, the stock has risen 1.8% to €807. The fair value is estimated to be €1,011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
Buy Or Sell Opportunity • Feb 21Now 22% undervaluedOver the last 90 days, the stock has risen 4.5% to €794. The fair value is estimated to be €1,024, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
Buy Or Sell Opportunity • Feb 21Now 22% undervaluedOver the last 90 days, the stock has risen 4.8% to €794. The fair value is estimated to be €1,022, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
Reported Earnings • Oct 05First half 2023 earnings released: EPS: €19.13 (vs €19.49 in 1H 2022)First half 2023 results: EPS: €19.13 (down from €19.49 in 1H 2022). Revenue: €376.4m (up 4.9% from 1H 2022). Net income: €39.9m (down 11% from 1H 2022). Profit margin: 11% (down from 13% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 5.1% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Jun 22Upcoming dividend of €8.50 per share at 1.0% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 26% and the cash payout ratio is 77%. Trailing yield: 1.0%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (2.8%).
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Director Elie Vannier was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • May 01Full year 2021 earnings releasedFull year 2021 results: Revenue: €608.8m (up 13% from FY 2020). Net income: €71.7m (up 42% from FY 2020). Profit margin: 12% (up from 9.4% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 11% compared to a 16% decline forecast for the industry in the United Kingdom.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 01First half 2021 earnings released: EPS €16.47 (vs €13.03 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €297.6m (up 6.2% from 1H 2020). Net income: €38.1m (up 27% from 1H 2020). Profit margin: 13% (up from 11% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 05Full year 2020 earnings released: EPS €21.88 (vs €22.96 in FY 2019)The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €538.3m (down 2.9% from FY 2019). Net income: €50.6m (down 4.7% from FY 2019). Profit margin: 9.4% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Jan 29New 90-day high: €955The company is up 3.0% from its price of €923 on 30 October 2020. The British market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 20% over the same period.
Is New 90 Day High Low • Dec 11New 90-day low: €546The company is down 45% from its price of €996 on 11 September 2020. The British market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 11Investor sentiment deteriorated over the past weekAfter last week's 38% share price decline to €546, the stock is trading at a trailing P/E ratio of 36.9x, down from the previous P/E ratio of 59.8x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 40%.
Valuation Update With 7 Day Price Move • Dec 10Market pulls back on stock over the past weekAfter last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 36.9x, down from the previous P/E ratio of 60.7x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Valuation Update With 7 Day Price Move • Dec 07Market pulls back on stock over the past weekAfter last week's 40% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.3x, down from the previous P/E ratio of 63.4x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Valuation Update With 7 Day Price Move • Dec 03Market pulls back on stock over the past weekAfter last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 63.2x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Valuation Update With 7 Day Price Move • Nov 30Market pulls back on stock over the past weekAfter last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 63.8x. This compares to an average P/E of 38x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Valuation Update With 7 Day Price Move • Nov 27Market pulls back on stock over the past weekAfter last week's 40% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 64.1x. This compares to an average P/E of 37x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Valuation Update With 7 Day Price Move • Nov 24Market pulls back on stock over the past weekAfter last week's 42% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 66.8x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Is New 90 Day High Low • Nov 20New 90-day low: €546The company is down 39% from its price of €897 on 21 August 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 20Market pulls back on stock over the past weekAfter last week's 42% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 66.8x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Is New 90 Day High Low • Oct 12New 90-day high: €1,036The company is up 8.0% from its price of €958 on 13 July 2020. The British market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 10.0% over the same period.
Reported Earnings • Oct 02First half earnings releasedOver the last 12 months the company has reported total profits of €53.7m, largely unchanged from the prior year. Total revenue was €547.4m over the last 12 months, up 1.0% from the prior year.